Global Strategic Business Report on Pulmonary Arterial Hypertension (PAH) Therapeutics 2018 – | Business

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.
This report analyzes the worldwide markets in US$ Million.

The global market is analyzed by the following Drug Class and Brands:
Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer)Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri*, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram)PDE-5 Inhibitors (Cialis/Adcirca, & Revatio)Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat)
The report profiles 31 companies including many key and niche players such as:
Actelion Pharmaceuticals Ltd (Switzerland)Bayer AG (Germany)Gilead Sciences, Inc. (US)Pfizer, Inc. (US)United Therapeutics Corporation (US)Lung Biotechnology PBC (US)

Leave a Reply

Your email address will not be published. Required fields are marked *